Will respond in more detail soon.
The effects seen in vivo are unusual. It seems as though there is something more to Bisantrene. For Carfilzomib to be completely useless in this model until Bisantrene is present, it seems the combination may be a result of increased cellular influx of Carfilzomib? I need to read more on this.
Ann: Bisantrene Highly Active in a Multiple Myeloma Mouse Model, page-33
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.89 |
Change
0.040(2.16%) |
Mkt cap ! $321.9M | |||
| Open | High | Low | Value | Volume |
| $1.85 | $1.89 | $1.85 | $28.41K | 15.36K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1805 | $1.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.89 | 1500 | 1 |
View Market Depth
| Last trade - 10.44am 17/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |